Mesoblast Limited (MESO)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mesoblast Limited (MESO) trades at $14.86 with AI Score 65/100 (Buy). Mesoblast Limited is a biopharmaceutical company focused on developing and commercializing allogeneic cellular medicines. Market cap: 2B, Sector: Healthcare.
Last analyzed: Mar 15, 2026Mesoblast Limited (MESO) Healthcare & Pipeline Overview
Mesoblast Limited, an Australian biopharmaceutical company, pioneers allogeneic cellular medicines using its mesenchymal lineage cell platform. Targeting cardiovascular, spine orthopedic, oncology, hematology, and immune-mediated diseases, Mesoblast is currently in Phase III clinical trials for several products, offering potential growth in regenerative medicine.
Investment Thesis
Mesoblast Limited presents a high-risk, high-reward investment opportunity within the regenerative medicine sector. The company's Phase III clinical trials for remestemcel-L, Rexlemestrocel-L, and MPC-06-ID represent potential near-term catalysts, with successful trial outcomes and regulatory approvals driving significant value. However, the company's negative profit and gross margins (-593.9% and -208.5%, respectively) highlight the substantial financial risks associated with drug development. Investor sentiment will likely be influenced by clinical trial data releases and regulatory decisions over the next 12-24 months. Strategic partnerships could also provide non-dilutive funding and market access.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $1.87 billion reflects investor expectations regarding the potential of Mesoblast's allogeneic cellular medicines.
- Negative P/E ratio of -18.41 indicates that the company is currently unprofitable, typical for biotechnology companies in the development phase.
- Profit Margin of -593.9% and Gross Margin of -208.5% reflect substantial R&D and operational expenses associated with clinical trials and product development.
- Beta of 0.85 suggests that the stock is less volatile than the overall market.
- No dividend is currently paid, as the company is focused on reinvesting earnings into research and development.
Competitors & Peers
Strengths
- Proprietary mesenchymal lineage cell platform.
- Advanced clinical pipeline with Phase III assets.
- Strategic partnerships with established pharmaceutical companies.
- Focus on unmet medical needs in regenerative medicine.
Weaknesses
- High R&D expenses and negative profitability.
- Reliance on clinical trial success and regulatory approvals.
- Competition from established pharmaceutical companies.
- Limited commercialized products and revenue streams.
Catalysts
- Upcoming: Data readouts from Phase III clinical trials for remestemcel-L in acute graft versus host disease.
- Upcoming: Results from Phase III trials of Rexlemestrocel-L for advanced chronic heart failure.
- Upcoming: Topline data from Phase III study of MPC-06-ID for chronic low back pain.
- Ongoing: Strategic partnerships for global expansion and commercialization.
- Ongoing: Regulatory approvals for key product candidates in major markets.
Risks
- Potential: Clinical trial failures or regulatory setbacks.
- Potential: Competition from established pharmaceutical companies and alternative therapies.
- Potential: Patent expirations and intellectual property challenges.
- Ongoing: High R&D expenses and negative profitability.
- Ongoing: Dependence on successful commercialization of product candidates.
Growth Opportunities
- Remestemcel-L for Acute Graft Versus Host Disease (aGVHD): Remestemcel-L targets steroid-refractory aGVHD, a life-threatening complication post-bone marrow transplant. The market for aGVHD treatment is substantial, with limited effective therapies. Successful commercialization could generate significant revenue, addressing a critical unmet need. Regulatory approval timelines are dependent on ongoing clinical trial data, with potential market entry within the next 2-3 years.
- Rexlemestrocel-L for Chronic Heart Failure: Rexlemestrocel-L aims to treat advanced chronic heart failure, a prevalent condition with high morbidity and mortality. Positive Phase III trial results could position Rexlemestrocel-L as a breakthrough therapy in a market dominated by symptomatic treatments. Market entry could occur within 3-5 years, pending regulatory approval and further clinical validation.
- MPC-06-ID for Chronic Low Back Pain: MPC-06-ID targets chronic low back pain due to degenerative disc disease, a widespread condition affecting a significant portion of the adult population. The non-opioid approach offers a potential alternative to traditional pain management strategies. Commercialization could occur within 3-5 years, contingent on successful trial outcomes and regulatory clearance.
- Strategic Partnerships for Global Expansion: Mesoblast's partnerships with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd., and Grünenthal provide access to key markets and expertise. These collaborations can accelerate product development, reduce financial risk, and expand the company's global footprint. Ongoing and future partnerships will be crucial for long-term growth and market penetration.
- Expansion into New Therapeutic Areas: Mesoblast's mesenchymal lineage cell platform has the potential to be applied to a wide range of diseases beyond its current pipeline. Exploring new therapeutic areas, such as autoimmune disorders or neurodegenerative diseases, could unlock significant growth opportunities. This expansion would require further R&D investment and clinical trials, with potential market entry in the long term (5+ years).
Opportunities
- Expansion into new therapeutic areas and indications.
- Securing additional partnerships for global market access.
- Advancements in regenerative medicine technologies.
- Increasing demand for novel therapies for chronic diseases.
Threats
- Clinical trial failures and regulatory setbacks.
- Competition from biosimilars and alternative therapies.
- Patent expirations and intellectual property challenges.
- Economic downturns and healthcare cost containment pressures.
Competitive Advantages
- Proprietary regenerative medicine technology platform based on mesenchymal lineage cells.
- Extensive patent portfolio protecting its cellular therapies.
- Advanced clinical trial pipeline with multiple products in Phase III development.
- Strategic partnerships with established pharmaceutical companies.
About MESO
Mesoblast Limited, incorporated in 2004 and headquartered in Melbourne, Australia, is a biopharmaceutical company focused on developing and commercializing innovative allogeneic cellular medicines. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells, which have the potential to treat a wide range of diseases. Mesoblast operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Its product pipeline targets areas such as cardiovascular disorders, spine orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. Currently, Mesoblast has several products in Phase III clinical trials, including remestemcel-L for steroid refractory acute graft versus host disease and acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L for advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. Additionally, the company is developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. Mesoblast has also established strategic partnerships with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd., and Grünenthal to expand its reach and develop cell therapies for various indications, including heart failure, heart attacks, wound healing, and chronic low back pain.
What They Do
- Develops allogeneic cellular medicines.
- Commercializes regenerative medicine products.
- Focuses on mesenchymal lineage cells.
- Targets cardiovascular diseases.
- Addresses spine orthopedic disorders.
- Develops treatments for oncology and hematology.
- Creates therapies for immune-mediated and inflammatory diseases.
Business Model
- Develops and patents allogeneic cellular therapies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approvals from agencies like the FDA.
- Commercializes approved products directly or through partnerships.
Industry Context
Mesoblast operates in the competitive biotechnology industry, which is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The regenerative medicine market is experiencing growth, driven by increasing demand for novel therapies for chronic diseases and unmet medical needs. Key competitors include companies like Cognition Therapeutics (COGT), Evelo Biosciences (EWTX), Galapagos NV (GLPG), Genprex (GPCR), and IBRX. Mesoblast's success depends on its ability to successfully navigate the regulatory landscape, secure partnerships, and demonstrate the efficacy and safety of its products.
Key Customers
- Patients suffering from cardiovascular diseases.
- Patients with spine orthopedic disorders.
- Patients undergoing cancer treatment.
- Patients with immune-mediated and inflammatory diseases.
Financials
Chart & Info
Mesoblast Limited (MESO) stock price: $14.86 (-0.79, -5.05%)
Latest News
-
Mesoblast to Host R&D Day on April 8, 2026
globenewswire.com · Mar 17, 2026
-
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
globenewswire.com · Mar 11, 2026
-
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
prnewswire.com · Mar 3, 2026
-
Mesoblast (NASDAQ:MESO) Shares Gap Down – What’s Next?
defenseworld.net · Mar 1, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MESO.
Price Targets
Wall Street price target analysis for MESO.
MoonshotScore
What does this score mean?
The MoonshotScore rates MESO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Mesoblast to Host R&D Day on April 8, 2026
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
Mesoblast (NASDAQ:MESO) Shares Gap Down – What’s Next?
Latest Mesoblast Limited Analysis
Leadership: Silviu Itescu
Chief Executive Officer
Silviu Itescu is the Chief Executive Officer of Mesoblast Limited. He has led the company since its inception, guiding its strategic direction and overseeing the development of its regenerative medicine technology platform. His background includes extensive experience in cell therapy and regenerative medicine. He is responsible for managing 73 employees. He has been instrumental in securing strategic partnerships and advancing the company's clinical pipeline.
Track Record: Under Silviu Itescu's leadership, Mesoblast has advanced multiple products into Phase III clinical trials and established key partnerships with pharmaceutical companies. He has overseen the development of the company's proprietary mesenchymal lineage cell platform and guided its expansion into new therapeutic areas. His strategic decisions have been pivotal in driving Mesoblast's growth and market position.
Mesoblast Limited ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For Mesoblast (MESO), each ADR represents a specific number of ordinary shares of Mesoblast Limited traded on its home market. This allows U.S. investors to invest in MESO without dealing with foreign exchanges.
- Home Market Ticker: Australian Securities Exchange (ASX), Australia
- ADR Level: 2
- ADR Ratio: 1:1
Common Questions About MESO
What does Mesoblast Limited do?
Mesoblast Limited is a biopharmaceutical company that develops and commercializes allogeneic cellular medicines. Its core technology revolves around mesenchymal lineage cells, which are used to create therapies for a range of conditions, including cardiovascular diseases, spine orthopedic disorders, and immune-mediated diseases. The company's business model involves developing these therapies, conducting clinical trials to prove their safety and efficacy, and then commercializing them either directly or through partnerships with other pharmaceutical companies. Mesoblast is currently focused on advancing its pipeline of Phase III product candidates towards regulatory approval and market launch.
What do analysts say about MESO stock?
Analyst coverage of Mesoblast Limited (MESO) is focused on the potential of its allogeneic cellular medicine platform and its pipeline of Phase III product candidates. Key valuation metrics include the potential peak sales of its lead drug candidates and the probability of regulatory approval. Growth considerations center on the successful completion of clinical trials, securing regulatory approvals, and establishing commercial partnerships. Analyst consensus is varied, reflecting the inherent risks and uncertainties associated with biotechnology companies in the clinical development stage. No buy or sell recommendations are made.
What are the main risks for MESO?
Mesoblast faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as negative results could delay or halt the development of its product candidates. Regulatory hurdles and potential rejection by regulatory agencies also pose a threat. Competition from established pharmaceutical companies and the emergence of alternative therapies could erode market share. Additionally, the company's high R&D expenses and negative profitability create financial risks, requiring it to secure additional funding to sustain operations.
What are the key factors to evaluate for MESO?
Mesoblast Limited (MESO) currently holds an AI score of 65/100, indicating moderate score. Key strength: Proprietary mesenchymal lineage cell platform.. Primary risk to monitor: Potential: Clinical trial failures or regulatory setbacks.. This is not financial advice.
How frequently does MESO data refresh on this page?
MESO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MESO's recent stock price performance?
Recent price movement in Mesoblast Limited (MESO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary mesenchymal lineage cell platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MESO overvalued or undervalued right now?
Determining whether Mesoblast Limited (MESO) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MESO?
Before investing in Mesoblast Limited (MESO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of the latest available reporting period.
- This is not investment advice. Conduct thorough research before making any investment decisions.